Treatment outcome of anaplastic thyroid cancer patients in Vietnam (period 2014-2022).

IF 3.3 4区医学 Q1 Medicine

European review for medical and pharmacological sciences Pub Date : 2024-10-01 DOI:10.26355/eurrev_202410_36867

N-V Dang, N-C Tin, N-D Duc, H T V Thanh

{"title":"Treatment outcome of anaplastic thyroid cancer patients in Vietnam (period 2014-2022).","authors":"N-V Dang, N-C Tin, N-D Duc, H T V Thanh","doi":"10.26355/eurrev_202410_36867","DOIUrl":null,"url":null,"abstract":"Objective: Anaplastic thyroid carcinoma (ATC) is an endocrine tumor with low incidence and one of the most aggressive human malignancies. The median survival is only 3-10 months, and the optimal therapeutic approach as well as prognostic factors have not been established. The aim of this study was to evaluate the long-term survival and good prognostic factors of patients with ATC.Patients and methods: The retrospective study used our institution's single-center database system. 31 patients with histopathological confirmation of anaplastic thyroid cancer from January 2014 to June 2022 were included.Results: 31 patients with ATC [11 males (35.5%), 20 females (64.5%); average age, 58.7 years] were identified, 32.3% were stage IVA, 32.3% stage IVB, and 35.4% IVC. The median overall survival (OS) of the entire cohort was 6.9 ± 1.45 months. The OS at two years was 12.1%. The female with no cervical lymph node metastasis, undergoing surgery, and tumor size < 6 cm were associated with improved OS. Patients undergoing surgery followed by chemoradiation therapy had the highest median OS (11 ± 1.83 months) and 21.8% of 2-year survival.Conclusions: Anaplastic thyroid carcinoma is a highly malignant tumor. Patients receiving surgical resection had better OS than patients without these treatments. The combination of surgery and chemoradiation could improve OS.","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 20","pages":"4442-4450"},"PeriodicalIF":3.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European review for medical and pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26355/eurrev_202410_36867","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Anaplastic thyroid carcinoma (ATC) is an endocrine tumor with low incidence and one of the most aggressive human malignancies. The median survival is only 3-10 months, and the optimal therapeutic approach as well as prognostic factors have not been established. The aim of this study was to evaluate the long-term survival and good prognostic factors of patients with ATC.

Patients and methods: The retrospective study used our institution's single-center database system. 31 patients with histopathological confirmation of anaplastic thyroid cancer from January 2014 to June 2022 were included.

Results: 31 patients with ATC [11 males (35.5%), 20 females (64.5%); average age, 58.7 years] were identified, 32.3% were stage IVA, 32.3% stage IVB, and 35.4% IVC. The median overall survival (OS) of the entire cohort was 6.9 ± 1.45 months. The OS at two years was 12.1%. The female with no cervical lymph node metastasis, undergoing surgery, and tumor size < 6 cm were associated with improved OS. Patients undergoing surgery followed by chemoradiation therapy had the highest median OS (11 ± 1.83 months) and 21.8% of 2-year survival.

Conclusions: Anaplastic thyroid carcinoma is a highly malignant tumor. Patients receiving surgical resection had better OS than patients without these treatments. The combination of surgery and chemoradiation could improve OS.

查看原文本刊更多论文

越南甲状腺无节细胞癌患者的治疗结果（2014-2022年）。

研究目的甲状腺无节细胞癌（ATC）是一种发病率较低的内分泌肿瘤，也是侵袭性最强的人类恶性肿瘤之一。中位生存期仅为 3-10 个月，最佳治疗方法和预后因素尚未确定。本研究旨在评估 ATC 患者的长期生存率和良好预后因素：这项回顾性研究使用了本机构的单中心数据库系统。纳入了2014年1月至2022年6月组织病理学确诊为甲状腺无节细胞癌的31例患者：31例ATC患者[男性11例（35.5%），女性20例（64.5%）；平均年龄58.7岁]中，32.3%为IVA期，32.3%为IVB期，35.4%为IVC期。整个组群的中位总生存期（OS）为 6.9 ± 1.45 个月。两年生存率为 12.1%。女性无颈部淋巴结转移、接受手术治疗以及肿瘤大小小于6厘米与OS的改善有关。接受手术和化疗的患者的中位生存期（11 ± 1.83个月）和2年生存率分别为21.8%：结论：甲状腺无节细胞癌是一种高度恶性肿瘤。结论：甲状腺无节细胞癌是一种高度恶性的肿瘤，接受手术切除的患者比未接受这些治疗的患者有更好的生存期。手术与化疗相结合可改善患者的生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European review for medical and pharmacological sciences 医学-药学

CiteScore

5.30

自引率

6.10%

发文量

906

审稿时长

2-4 weeks

期刊介绍： European Review for Medical and Pharmacological Sciences, a fortnightly journal, acts as an information exchange tool on several aspects of medical and pharmacological sciences. It publishes reviews, original articles, and results from original research. The purposes of the Journal are to encourage interdisciplinary discussions and to contribute to the advancement of medicine. European Review for Medical and Pharmacological Sciences includes: -Editorials- Reviews- Original articles- Trials- Brief communications- Case reports (only if of particular interest and accompanied by a short review)